[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Investor Update - February 1, 2024 Category: Pharmaceuticals Source Type: news
Zydus launches pill for prostate cancer patients
The drug firm said the medication would cost Rs 6,995 per month, which is 50 per cent less than the currently available injectable options. "With this, the treatment for prostate cancer in India can now be made completely oral, thus helping patients lead a better quality of life," Zydus Lifesciences said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 30, 2024 Category: Pharmaceuticals Source Type: news
' Brush Biopsy' Could Be Easy Dental Office Cancer Screen
MONDAY, Jan. 22, 2024 -- A newly developed “brush biopsy” allows dentists to screen for the most common form of mouth cancer, a new study reports.Dentists use a small brush to gently collect cells from potentially cancerous lesions inside the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 22, 2024 Category: General Medicine Source Type: news
Artificial intelligence for classification and detection of oral mucosa lesions on photographs: a systematic review and meta-analysis
ConclusionsAI
may assist in oral mucosa lesion screening while the expected accuracy
gains or further health benefits remain unclear so far.Clinical relevanceArtificial
intelligence assists oral mucosa lesion screening and may foster more
targeted testing and referral in the hands of non-specialist providers,
for example. So far, it remains unclear if accuracy gains compared with
specialized can be realized. (Source: Dental Technology Blog)
Source: Dental Technology Blog - January 18, 2024 Category: Dentistry Source Type: news
Independent Research Data On Hepatic Artery Infusion (HAI) Therapy To Be Featured At ASCO GI Cancer Symposium
Researchers from several top academic medical institutions will present their findings related to HAI therapy through live presentations, oral abstracts, and posters at the symposium. BOSTON, Jan. 16, 2024 /PRNewswire-PRWeb/ -- Intera Oncology, maker of the only FDA-approved implantable... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 16, 2024 Category: Pharmaceuticals Tags: TRI TDS Source Type: news
Revealed: How to check your OWN mouth for signs of cancer
Dr Michael Ho, a face, neck and mouth cancer consultant at the University of Leeds, shares his step-by-step guide of the signs to check for. (Source: the Mail online | Health)
Source: the Mail online | Health - January 13, 2024 Category: Consumer Health News Source Type: news
Prior Auth Tied to Delays, Discontinuation of Cancer Meds Prior Auth Tied to Delays, Discontinuation of Cancer Meds
The introduction of a new prior authorization requirement for an established oral anticancer regimen led to more treatment delays and discontinuations among Medicare beneficiaries.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 4, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
BDR Pharmaceuticals introduces prostate cancer treatment drug in oral solution form
It is a more patient-friendly way to tackle prostate cancer. It can help improve patient compliance to a great extent, Badiger said. The company said introducing the Drug Controller General of India (DCGI)approved new drug delivery system will make it more affordable and accessible in India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 2, 2024 Category: Pharmaceuticals Source Type: news
Alveolar bone loss and tooth loss contribute to increase in cancer mortality among older patients
ConclusionOur
results indicate that older patients suffering from tooth loss or
alveolar bone loss are at increased risks of cancer mortality,
especially for total cancer and LOP cancer. (Source: Dental Technology Blog)
Source: Dental Technology Blog - December 28, 2023 Category: Dentistry Source Type: news
The Most Exciting New Advancements in Managing and Treating Lupus
The case study involved just one patient: a 20-year-old woman with severe systemic lupus erythematosus (SLE). But the study’s results were so dramatic that they appeared in 2021 in the New England Journal of Medicine.
The woman received a type of cell therapy called CAR-T, which in the past has been used primarily to treat cancer. CAR-T cell therapy involves altering a patient’s immune cells so that they identify and attack problems or pathogens. In people with cancer, that attack is aimed at the diseased cells. But in the NEJM case study, the therapy was directed at the woman’s own B cells,...
Source: TIME: Health - December 27, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate Source Type: news
Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study
Crinetics Pharmaceuticals Inc CRNX released initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound being developed for acromegaly and CS. Carcinoid syndrome occurs when a rare cancerous tumor, called a…#phase2 #scottstruthers #crinetics #fda #enrollment (Source: Reuters: Health)
Source: Reuters: Health - December 19, 2023 Category: Consumer Health News Source Type: news
6 Myths About IBD, Debunked
Michelle Pickens’ symptoms escalated in college. At the time, she was throwing up at least once a day, and experiencing frequent nausea, abdominal pain, diarrhea, and constipation. Juggling classes with work at a design studio became an extreme exercise in perseverance. She knew in her gut that something was wrong.
Yet three different doctors “wrote it off as stress,” says Pickens, now 32, who lives in Annapolis, Md. Lab work and procedures to see inside her gastrointestinal tract showed nothing abnormal. “No one wanted to dig deeper,” she recalls. In a final act of desperation, Pickens sa...
Source: TIME: Health - December 18, 2023 Category: Consumer Health News Authors: Lindsay Lyon Tags: Uncategorized healthscienceclimate Source Type: news
Over 32 cr people have been screened for oral, breast, cervical cancer at Ayushman Arogya Mandirs
The Indian government reveals that over 1,63,000 Ayushman Arogya Mandirs nationwide have screened millions for oral, breast, and cervical cancers. These screenings are part of primary healthcare efforts under the National Health Mission. The Health Minister highlights the referral process for positive cases to designated healthcare facilities. Additionally, infrastructure, awareness programs, and financial assistance schemes, including the PMJAY and Rashtriya Arogya Nidhi, are aiding cancer prevention and treatment. (Source: The Economic Times)
Source: The Economic Times - December 15, 2023 Category: Consumer Health News Source Type: news
FDA Approves Merck ’s Welireg (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
RAHWAY, N.J.--(BUSINESS WIRE) December 14, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Welireg, an oral hypoxia-inducible factor-2... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 14, 2023 Category: Drugs & Pharmacology Source Type: news
New data for Roche ’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting& Exposition, 9-12 December ...
Source: Roche Media News - December 11, 2023 Category: Pharmaceuticals Source Type: news
